Clinico-pathological and biomolecular findings in Italian patients with multiple cutaneous neurofibromas

Hereditary Cancer in Clinical Practice

Volumn 9, Issue 1, 2011, Pages

  Ponti, Giovanni ^a   Losi, Lorena ^b   Martorana, Davide ^c   Priola, Manuela ^d   Boni, Elisa ^a   Pollio, Annamaria ^e   Neri, Tauro M ^c   Seidenari, Stefania ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c UNIVERSITY HOSPITAL OF PARMA   (Italy)

^d CNR   (Italy)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROFIBROMIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER SURGERY; CLINICAL EXAMINATION; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; CUTANEOUS NEUROFIBROMA; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; EXON; FAMILY; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GENE DELETION; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GENETIC CODE; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; GERM LINE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; ITALY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MOLECULAR GENETICS; NEUROFIBROMA; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PEDIGREE; PROTEIN ANALYSIS; PROTEIN TRUNCATION TEST; PSEUDOGENE; RNA SPLICING; SEMI STRUCTURED INTERVIEW; SENSITIVITY AND SPECIFICITY; SKIN DEFECT; SKIN TUMOR; SOMATIC MUTATION; SYMPTOM; TUMOR SUPPRESSOR GENE; UNIVERSITY HOSPITAL; VISCERAL METASTASIS;

EID: 84861970921     PISSN: 17312302     EISSN: 18974287     Source Type: Journal    
DOI: 10.1186/1897-4287-9-6     Document Type: Article

References (31)

1. Halliday AL, Sobel RA, Martuza RL. Benign spinal nerve sheath tumors: their occurrence sporadically and in neurofibromatosis type 1 and 2. J Neurosurg 1991, 74:248-253.
2. Richardson RR, Siqueira EB, Oi S, Nunez C. Neurogenic tumors of the brachial plexus: report of two cases. Neurosurgery 1979, 4:66-70.
3. Rubistein LJ. The malformative central nervous system lesions in central and peripheral forms of neurofibromatosis. A neuro-pathological study of 22 cases. Ann NY Acad Sci 1986, 486:14-29.
4. Rasmussen SA, Friedman JM. NF1 gene and neurofibromatosis 1. Am J Epidemiol 2000, 151:33-40.
5. National Institute of Health Consensus Development Conference Statement Neurofibromatosis. Arch Neurol Chicago 1988, 45:575-578.
6. Huson SM, Harper PS, Compston DA. Von Recklingausen neurofibromatosis. A clinical and population study in south-east Wales. Brain 1988, 111:1355-1381.
7. Evans DG, Baser ME, McGaughran J, Sharif S, Howard E, Moran A. Malignant peripheral nerve sheath tumors in neurofibromatosis 1. J Med Genet 2002, 39:311-314.
8. Korf BR, Schneider G, Poussaint TY. Structural anomalies revealed by neuroimaging studies in the brains of patients with neurofibromatosis type 1 and large deletions. Genet Med 1999, 1:136-140.
9. Ferner RE, Huson SM, Thomas N, Moss C, Willshaw H, Evans DG, Upadhyaya M, Towers R, Gleeson M, Steiger C, Kirby A. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet 2007, 44:81-88.
10. Heim RA, Kam-Morgan LN, Binnie CG, Corns DD, Cayouette MC, Farber RA, Aylsworth AS, Silverman LM, Luce MC. Distribution of 13 truncating mutations in the neurofibromatosis 1 gene. Hum Mol Genet 1995, 4:975-981.
11. Upadhyaya M, Osborn MJ, Maynard J, Kim MR, Tamanoi F, Cooper DN. Mutational and functional analysis of the neurofibromatosis type 1 (NF1) gene. Hum Genet 1997, 99:88-92.
12. Li Y, O'Connell P, Breidenbach HH, Cawthon R, Stevens J, Xu G, Neil S, Robertson M, White R, Viskochil D. Genomic organization of the neurofibromatosis 1 gene (NF1). Genomics 1995, 25:9-18.
13. De Luca A, Bottillo I, Dasdia MC, Morella A, Lanari V, Bernardini L, Divona L, Giustini S, Sinibaldi L, Novelli A, Torrente I, Schirinzi A, Dallapiccola B. Deletions of NF1 gene and exons detected by multiplex ligation-dependent probe amplification. J Med Genet 2007, 44:800-808.
14. De Luca A, Schirinzi A, Buccino A, Bottillo I, Sinibaldi L, Torrente I, Ciavarella A, Porciello R, Giustini S, Calvieri S, Dallapiccola B. Novel and recurrent mutations in the NF1 gene in Italian patients with neurofibromatosis type 1. Hum Mutat 2004, 23:629.
15. Ahlquist T, Bottillo I, Danielsen SA, Meling GI, Rognum TO, Lind GE, Dallapiccola B, Lothe RA. RAS signaling in colorectal carcinomas through alteration of RAS, RAF, NF1, and/or RASSF1A.A. Neoplasia 2008, 10:680-6.
16. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25:402-408. Korf BR. Diagnostic outcome in children with multiple cafe' au lait spots. Pediatrics1992;90:924-7.
17. Kim DH, Murovic JA, Tiel RL, Moes G, Kline DG. A series of 397 peripheral neural sheath tumors: 30-year experience at Louisiana State University Health Sciences Center. J Neurosurg 2005, 102:246-255.
18. Jadayel D, Fair P, Upadhayaya M. Paternal origin of new mutations in Von Recklinghausen neurofibromatosis. Nature 1990, 343:558-559.
19. Riccardi V, Dobson C, Chakraborty R, Bontke C. The pathophysiology of neurofibromatosis. IX: Paternal age effect on the origin of new mutations. Am J Med Genet 1984, 18:169-176.
20. Sergeyev AS. On the mutation rate of neurofibromatosis. Hum Genet 1975, 28:129-138.
21. Atit RP, Crowe MJ, Greenhalgh DG, Wenstrup RJ, Ratner N. The Nf1 tumor suppressor regulates mouse skin wound healing, fibroblast proliferation, and collagen deposited by fibroblasts. J Invest Dermatol 1999, 112:835-842.
22. Karvonen SL, Kallioinen M, Yla-Outinen H, Poyhonen M, Oikarinen A, Peltonen L. Occult neurofibroma and increased S100 protein in the skin of patients with neurofibromatosis type 1: new insight to the etiopathomechanism of neurofibromatosis. Arch Dermatol 2000, 136:1207-1209.
23. Riccardi VM. Of mass and men: neurofibromas and histogenesis. Arch Dermatol 2000, 136:1257-1258.
24. Yla-Outinen H, Aaltonen V, Bjorkstrand AS, Hirvonen O, Lakkakorpi J, Vaha-Kreula M, Laato M, Peltonen J. Upregulation of tumor suppressor protein neurofibromin in normal human wound healing and in vitro evidence for platelet derived growth factor (PDGF) and transforming growth factor-beta 1 (TGF-beta1) elicited increase in neurofibromin mRNA steady-state levels in dermal fibroblasts. J Invest Dermatol 1998, 110:232-237.
25. Griffiths DF, Williams GT, Williams ED. Duodenal carcinoid tumours, phaeochromocytoma and neurofibromatosis: islet cell tumour, phaeochromocytoma and the von Hippel-Lindau complex: two distinctive neuroendocrine syndromes. Q J Med 1987, 64:769-782.
26. Fuller CE, Williams GT. Gastrointestinal manifestations of type 1 neurofibromatosis (von Recklinghausen's disease). Histopathology 1991, 19:1-11.
27. Zoller ME, Rembeck B, Oden A, Samuelsson M, Angervall L. Malignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish population. Cancer 1997, 79:2125-2131.
28. Takazawa Y, Sakurai S, Sakuma Y, Ikeda T, Yamaguchi J, Hashizume Y, Yokoyama S, Motegi A, Fukayama M. Gastrointestinal stromal tumors of neurofibromatosis type 1 (von Recklighausen's disease). Am J Surg Pathol 2005, 29:755-763.
29. Li H, Velasco-Migual S, Vass WC, Parada LF, DeClue JE. Epidermal growth factor receptor signaling pathways are associated with tumorigenesis in the NF1: p53 mouse tumor model. Cancer Res 2002, 62:4507-4513.
30. Ling BC, Wu J, Miller SJ, Monk KR, Shamekh R, Rizvi TA, Decourten-Myers G, Vogel KS, DeClue JE, Ratner N. Role for the epidermal growth factor receptor in neurofibromatosis-related peripheral nerve tumorigenesis. Cancer Cell 2005, 7:65-75.
31. Perry A, Kunz S, Fuller CE, Banerjee R, Marley EF, Liapis H, Watson MA, Gutmann DH. Differential NF1, p16, and EGFR patterns by interphase cytogenetics (FISH) in malignant peripheral nerve sheath tumor (MPNST) and morphologically similar spindle cell neoplasms. J Neuropathol Exp Neurol 2002, 61:702-709.